These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19388720)

  • 1. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.
    De Backer TL; Vander Stichele RH; Van Bortel LM
    Drug Saf; 2009; 32(4):283-91. PubMed ID: 19388720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buflomedil for intermittent claudication.
    De Backer TL; Vander Stichele RH; Bogaert MG
    Cochrane Database Syst Rev; 2001; (1):CD000988. PubMed ID: 11279700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buflomedil for intermittent claudication.
    de Backer TL; Bogaert M; Vander Stichele R
    Cochrane Database Syst Rev; 2007 Oct; (4):CD000988. PubMed ID: 17943749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buflomedil for intermittent claudication.
    de Backer TL; Bogaert M; Vander Stichele R
    Cochrane Database Syst Rev; 2008 Jan; (1):CD000988. PubMed ID: 18253982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buflomedil for intermittent claudication.
    de Backer TL; Vander Stichele R
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD000988. PubMed ID: 23543509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
    Walker GA; Mac Hannaford JC
    Fundam Clin Pharmacol; 1995; 9(4):387-94. PubMed ID: 8566940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011.
    Bucolo C; Longo L; Camillieri G; Drago F; Salomone S
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1190-6. PubMed ID: 22855302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral vasoactive medication in intermittent claudication: utile or futile?
    De Backer TL; Vander Stichele RH; Warie HH; Bogaert MG
    Eur J Clin Pharmacol; 2000 Jun; 56(3):199-206. PubMed ID: 10952473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline for intermittent claudication.
    Salhiyyah K; Forster R; Senanayake E; Abdel-Hadi M; Booth A; Michaels JA
    Cochrane Database Syst Rev; 2015 Sep; 9(9):CD005262. PubMed ID: 26417854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of long-term safety data with buflomedil.
    Bachand RT; Dubourg AY
    J Int Med Res; 1990; 18(3):245-52. PubMed ID: 2193838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ; Grigoriadou M; Ifanti G; Raptis SA
    Int Angiol; 2001 Dec; 20(4):337-44. PubMed ID: 11782701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
    Rosas G; Cerdeyra C; Lucas MA; Parano JR; Villa JJ
    Angiology; 1981 May; 32(5):291-7. PubMed ID: 7235299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Van den Brande P; Maurel A
    Angiology; 1998 Feb; 49(2):105-14. PubMed ID: 9482510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.
    Bourguignon L; Ducher M; Matanza D; Bleyzac N; Uhart M; Odouard E; Maire P; Goutelle S
    Fundam Clin Pharmacol; 2012 Apr; 26(2):279-85. PubMed ID: 22004557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
    Diehm C; Eckstein M; Hübsch-Müller C
    Vasa; 1989; 18(1):40-7. PubMed ID: 2648691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.